TT
The startup is focused on developing a novel protein-based analgesic derived from CNRS and IBDM research to treat neuropathic and inflammatory pain. This approach aims to provide rapid relief for patients suffering from chronic conditions such as migraines, muscle pain, and neuropathies.
Updated 3 months ago
Funding
$6.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup is focused on developing a novel protein-based analgesic derived from CNRS and IBDM research to treat neuropathic and inflammatory pain. This approach aims to provide rapid relief for patients suffering from chronic conditions such as migraines, muscle pain, and neuropathies.